BACKGROUND: The first cases of coronavirus disease (COVID-19) in Brazil were diagnosed in February 2020. Our Emergency Department (ED) was designated as a COVID-19 exclusive service. We report our first 500 confirmed COVID-19 pneumonia patients. METHODS: From 14 March to 16 May 2020, we enrolled all patients admitted to our ED that had a diagnosis of COVID-19 pneumonia. Infection was confirmed via nasopharyngeal swabs or tracheal aspirate PCR. The outcomes included hospital discharge, invasive mechanical ventilation, and in-hospital death, among others. RESULTS: From 2219 patients received in the ED, we included 506 with confirmed COVID-19 pneumonia. We found that 333 patients were discharged home (65.9%), 153 died (30.2%), and 20 (3.9%) remained in the hospital. A total of 300 patients (59.3%) required ICU admission, and 227 (44.9%) needed invasive ventilation. The multivariate analysis found age, number of comorbidities, extension of ground glass opacities on chest CT and troponin with a direct relationship with all-cause mortality, whereas dysgeusia, use of angiotensin converting enzyme inhibitor or angiotensin-ii receptor blocker and number of lymphocytes with an inverse relationship with all-cause mortality. CONCLUSIONS: This was a sample of severe patients with COVID-19, with 59.2% admitted to the ICU and 41.5% requiring mechanical ventilator support. We were able to ascertain the outcome in majority (96%) of patients. While the overall mortality was 30.2%, mortality for intubated patients was 55.9%. Multivariate analysis agreed with data found in other studies although the use of angiotensin converting enzyme inhibitor or angiotensin-ii receptor blocker as a protective factor could be promising but would need further studies. TRIAL REGISTRATION: The study was registered in the Brazilian registry of clinical trials: RBR-5d4dj5.
BACKGROUND: The first cases of coronavirus disease (COVID-19) in Brazil were diagnosed in February 2020. Our Emergency Department (ED) was designated as a COVID-19 exclusive service. We report our first 500 confirmed COVID-19 pneumoniapatients. METHODS: From 14 March to 16 May 2020, we enrolled all patients admitted to our ED that had a diagnosis of COVID-19 pneumonia. Infection was confirmed via nasopharyngeal swabs or tracheal aspirate PCR. The outcomes included hospital discharge, invasive mechanical ventilation, and in-hospital death, among others. RESULTS: From 2219 patients received in the ED, we included 506 with confirmed COVID-19 pneumonia. We found that 333 patients were discharged home (65.9%), 153 died (30.2%), and 20 (3.9%) remained in the hospital. A total of 300 patients (59.3%) required ICU admission, and 227 (44.9%) needed invasive ventilation. The multivariate analysis found age, number of comorbidities, extension of ground glass opacities on chest CT and troponin with a direct relationship with all-cause mortality, whereas dysgeusia, use of angiotensin converting enzyme inhibitor or angiotensin-ii receptor blocker and number of lymphocytes with an inverse relationship with all-cause mortality. CONCLUSIONS: This was a sample of severe patients with COVID-19, with 59.2% admitted to the ICU and 41.5% requiring mechanical ventilator support. We were able to ascertain the outcome in majority (96%) of patients. While the overall mortality was 30.2%, mortality for intubated patients was 55.9%. Multivariate analysis agreed with data found in other studies although the use of angiotensin converting enzyme inhibitor or angiotensin-ii receptor blocker as a protective factor could be promising but would need further studies. TRIAL REGISTRATION: The study was registered in the Brazilian registry of clinical trials: RBR-5d4dj5.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Jane Y Tong; Amanda Wong; Daniel Zhu; Judd H Fastenberg; Tristan Tham Journal: Otolaryngol Head Neck Surg Date: 2020-05-05 Impact factor: 3.497
Authors: D H Frank Gommans; Joris Nas; Sara-Joan Pinto-Sietsma; Yvonne Koop; Regina E Konst; Frans Mensink; Goaris W A Aarts; Lara S F Konijnenberg; Kimberley Cortenbach; Dominique V M Verhaert; Jos Thannhauser; Jan-Quinten Mol; Maxim J P Rooijakkers; Jacqueline L Vos; Anouke van Rumund; Priya Vart; Robert-Jan Hassing; Jan-Hein Cornel; C Peter C de Jager; Michel M van den Heuvel; Hans G van der Hoeven; Annelies Verbon; Yigal M Pinto; Niels van Royen; Roland R J van Kimmenade; Peter W de Leeuw; Michiel A van Agtmael; Paul Bresser; Wiek H van Gilst; Anton Vonk-Noordergraaf; Jan G P Tijssen; Niels van Royen; C Peter C de Jager; Michel M van den Heuvel; Hans G van der Hoeven; Annelies Verbon; Yigal M Pinto; Roland R J van Kimmenade Journal: Am Heart J Date: 2020-05-21 Impact factor: 4.749
Authors: R Gorjão; S M Hirabara; L N Masi; T D A Serdan; R B Gritte; E Hatanaka; T Souza-Siqueira; A C Pithon-Curi; T M de Lima; T C Pithon-Curi; J F M Marchini; M C C Machado; H P Souza; R Curi Journal: Braz J Med Biol Res Date: 2022-06-22 Impact factor: 2.904
Authors: Rodrigo A Brandão Neto; Julio F Marchini; Lucas O Marino; Julio C G Alencar; Felippe Lazar Neto; Sabrina Ribeiro; Fernando S Valente; Hassan Rahhal; Luz Marina Gomez Gomez; Caue G Bueno; Carine C Faria; Victor P da Cunha; Eduardo Padrão; Irineu T Velasco; Heraldo Possolo de Souza Journal: PLoS One Date: 2021-03-04 Impact factor: 3.240
Authors: Marcel Cerqueira Cesar Machado; Roberto Kalil Filho; Ibrahim Ahmad Hussein El Bacha; Irai Santana de Oliveira; Cristiane Maria de Freitas Ribeiro; Heraldo Possolo de Souza; Edson Roberto Parise Journal: Am J Case Rep Date: 2022-08-18
Authors: Izabel Marcilio; Felippe Lazar Neto; Andre Lazzeri Cortez; Anna Miethke-Morais; Hillegonda Maria Dutilh Novaes; Heraldo Possolo de Sousa; Carlos Roberto Ribeiro de Carvalho; Anna Sara Shafferman Levin; Juliana Carvalho Ferreira; Nelson Gouveia Journal: PLoS One Date: 2022-09-28 Impact factor: 3.752